Skip to content

Antimicrobial Resistance in Acute Cholangitis

Exploring Antimicrobial Resistance in Patients With Acute Cholangitis Undergoing ERCP: A Prospective Multicentre Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06197984
Acronym
ARISE
Enrollment
1435
Registered
2024-01-10
Start date
2024-01-08
Completion date
2026-01-05
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Diseases, Cholangitis Acute, Choledocholithiasis, Jaundice; Malignant, Jaundice, Obstructive

Keywords

Acute Cholangitis, Antibiotics, MultiDrug Resistance (MDR)

Brief summary

This study prospectively explores antimicrobial resistance in patients with acute cholangitis undergoing ERCP procedures. By analyzing patient profiles, microbial cultures, and treatment outcomes, the current study seeks to identify specific patterns of resistance, assess the effectiveness of current antimicrobial therapies, and explore potential strategies to optimize treatment regimens.

Detailed description

Given the extensive utilization of antibiotics and the worldwide rise of multidrug-resistant organisms, there are ongoing initiatives to ascertain microbiological traits and discern patterns of drug resistance associated with intra-abdominal infections. Microbial cultures from bile and blood samples will be established and characterized using appropriate methodologies. For patients with moderate and severe acute cholangitis (AC), blood cultures will be initiated upon admission, adhering to the Tokyo Guidelines for AC 2018 recommendations. Bile specimens will be obtained after cannulation through the sphincterotome before the therapeutic intervention. Initially, a minimum of 5 mL of the procured bile will be discarded, followed by the collection of an additional 5 mL in a sterile vessel containing a medium conducive to both anaerobic and aerobic bacterial cultures. The samples will undergo a minimum incubation period of seven days at 37 °C until microbial proliferation becomes evident. Antibiotic susceptibility assessments, specifically minimum inhibitory concentration (MIC), will be performed and interpreted according to established guidelines.The analysis of samples will occur within the laboratory of each respective center, with antibiograms conducted in accordance with established protocols.

Interventions

PROCEDUREERCP

ERCP will serve as the exclusive therapeutic modality, aided by a therapeutic duodenoscope to access the common bile duct using a guidewire.

Sponsors

Emergency County Hospital Pius Brinzeu; Timisoara, Romania
Lead SponsorNETWORK
Carol Davila University of Medicine and Pharmacy
CollaboratorOTHER
Grigore T. Popa University of Medicine and Pharmacy
CollaboratorOTHER
Bucharest Emergency Hospital
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with acute cholangitis * Ability to provide an informed consent * Age over 18 years * Any gender

Exclusion criteria

* Age under 18 * Pregnancy * Post-ERCP perforation * The patient's decision to abstain from study enrollment * Patients unable to express informed consent * Patients from whom a bile sample could not be collected.

Design outcomes

Primary

MeasureTime frameDescription
Exploring antimicrobial resistance of bile cultures and characterizing bacterial profile2 yearsThe primary objective of this prospective, multicenter study is to meticulously characterize the bacterial profile and assess the antimicrobial resistance of bile cultures in patients diagnosed with acute cholangitis undergoing ERCP procedures. By employing advanced microbiological analyses, the investigators aim to identify specific bacterial strains and their resistance profiles, providing comprehensive insights into the dynamics of infection. This primary outcome will contribute to the development of tailored antimicrobial strategies, optimizing the management and treatment outcomes for individuals with acute cholangitis.

Secondary

MeasureTime frameDescription
Isolated bacteria and the etiology of obstructive biliary disease2 yearsSecondary objectives encompass exploring the correlation between isolated bacteria and the etiology of obstructive biliary disease.
Multidrug-Resistance (MDR)2 yearsAdditionally, the investigators aim to determine the occurrence and frequency of multidrug-resistant (MDR) organisms and sentinel microorganisms in bile samples.
ERCP naive patients vs. patients with a history of ERCP2 yearsFurthermore, the investigators are going to explore potential variations in the biliary microbial community, making comparisons between patients with no prior ERCP experience (naive) and those with a history of ERCP procedures. This comprehensive secondary outcome analysis seeks to unravel microbial relationships, antibiotic resistance patterns, and the impact of procedural history on biliary microbial communities in the context of acute cholangitis.

Countries

Romania

Contacts

PRINCIPAL_INVESTIGATORBogdan Miutescu, MD,PhD

Emergency County Hospital Pius Brinzeu; Timisoara, Romania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026